top of page
Search

Diagnosed with PD after 70 - try Mucuna first.

Updated: Apr 6, 2024




Navigating Parkinson's Beyond Age 70: A Different Journey


A Parkinson's diagnosis after the age of 70 opens up a range of options on the path to treatment.


Later onset Parkinson's typically presents with gentler symptoms, more easily managed with a more wholistic intervention. In addition, the primary focus for older patients revolves around diligently addressing cardiac and general health concerns. The clinical aim is to avoid any potential conflicts with current medications. To achieve this, the suggestion is to begin with modest doses of Mucuna (MacuDopa), the ideal being our 700 mg HPLC formula at 63%. The dose and frequency can then be gradually increasing with oversight of a GP or neurologist.


Treatment options at this stage understandably call for a cautious mindset. If the clinician is considering explorating the use of mucuna, the key is to start with conservative doses, allowing for a gradual progression in dosage in line with symptom management.

This approach is centered on well-being and comfort as doctor and patient navigate the treatment together, ensuring that each step is taken with care and consideration.


 
 

Recent Posts

See All

'Living well naturally with Parkinson's until there is a cure'.

  • Facebook
  • Twitter

Useful Links

Contact Us

hello@macudopa.com

Call or text us:  +44 (0) 7931 293 934 

Monday to Friday 9am to 5pm UK time

*Disclaimer UK

All the information included on this website is for information purposes only. It is not intended to treat or diagnose any medical condition, nor is it intended as a substitute for medical advice.  If you are concerned about any symptoms please visit your GP for investigation and diagnosis. For medical diagnosis and treatment please consult your specialist or doctor.

© 2025 CogniBrain LTD. All rights reserved.

The content provided in connection with MacuDopa, including but not limited to text, product descriptions, research summaries, FAQs, and proprietary information regarding our Mucuna-based formulation, is protected under copyright law. Unauthorized use, reproduction, or distribution of any part of this content is prohibited without prior written permission from CogniBrain LTD. MacuDopa and related intellectual property are the sole property of CogniBrain LTD, and any infringement will be pursued to the fullest extent permitted by law.

bottom of page